Table 1.
Baseline data of 139 HBV-related HCC patients.
| Item | Group 1 (n = 54) | Group 2 (n = 85) | χ2 | P value |
|---|---|---|---|---|
| Age (≥55) | 24/54 (44.40%) | 45/85 (52.90%) | 0.954 | 0.329 |
| Child-Pugh Score(A) | 36/54 (66.70%) | 68/85 (80.00%) | 3.116 | 0.078 |
| PS Score (≤1’) | 41/54 (75.90%) | 72/85 (84.70%) | 1.674 | 0.196 |
| History of hypertension | 9/54 (16.70%) | 19/85 (22.40%) | 0.664 | 0.415 |
| History of diabetes | 4/54 (7.40%) | 14/85 (16.50%) | 2.406 | 0.121 |
| Ascites | 46/54 (85.20%) | 73/85 (84.90%) | 0.130 | 0.909 |
| Loco-regional therapies | ||||
| Argon–Helium cryosurgical | 22/54 (40.70%) | 37/85 (43.50%) | 0.484 | 0.922 |
| microwave ablation | 9/54 (16.70%) | 16/85 (18.80%) | ||
| interventional therapy | 14/54 (25.90%) | 21/85 (24.70%) | ||
| none | 9/54 (16.70%) | 11/85 (12.90%) | ||
| BCLC Stage (B) | 40/54 (74.10%) | 66/85 (77.60%) | 0.233 | 0.620 |
Group1, lenvatinib plus sintilimab treatment group; Group2, lenvatinib monotherapy group.
Hepatocellular Carcinoma (HCC); Performance status (PS); Barcelona Clinic Liver Cancer (BCLC); Loco-regional therapies (LRT).